electroCore, Inc. (ECOR)
| Market Cap | 124.55M |
| Revenue (ttm) | 3.24M |
| Net Income (ttm) | -25.69M |
| Shares Out | 44.03M |
| EPS (ttm) | -0.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $3.05 |
| Previous Close | $2.74 |
| Change ($) | 0.31 |
| Change (%) | 11.31% |
| Day's Open | 3.12 |
| Day's Range | 2.86 - 3.29 |
| Day's Volume | 6,258,737 |
| 52-Week Range | 0.33 - 3.29 |
ROCKAWAY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Health Improvement Scotland (“HIS”) ...
ROCKAWAY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Centers for Medicare and Medicaid Se...
Full year 2020 revenue expected at the upper end of previously announced guidance range of $3.3M - $3.5M; greater than 40% growth over full year 2019 revenue of $2.4M
ROCKAWAY, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement wit...
BASKING RIDGE, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management is scheduled to pres...
electroCore's (ECOR) CEO Dan Goldberger on Q3 2020 Results - Earnings Call Transcript
Shares of electroCore (NASDAQ:ECOR) moved higher by 10.83% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 71.43% over the past year...
On Thursday, November 12, electroCore (NASDAQ: ECOR) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
Conference Call to be Held at 4:30pm Eastern Time Conference Call to be Held at 4:30pm Eastern Time
Third quarter 2020 Revenue expected to exceed $1 million , representing an increase of greater than 35% sequentially and greater than 50% over Q3 2019
ITP program providing reimbursement for gammaCore ™ extended to March. 31, 2021 with option for additional three years
BASKING RIDGE, N.J., Sept. 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Department of Veterans Aff...
Comprehensive telehealth platform to facilitate the efficient procurement of gammaCore Sapphire™ CV (non-invasive vagus nerve stimulator) by known or suspected COVID-19 patients Comprehensive ...
BASKING RIDGE, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, chief execut...
BASKING RIDGE, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that management is scheduled to p...
BASKING RIDGE, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitl...
Reimbursement for gammaCore™ in England Reimbursement for gammaCore™ in England
Rock-solid financial stats and a highly specific medical technology add up to a compelling argument in favor of ECOR stock. The post Make ElectroCore a Core Holding after an Outstanding Q2 app...
electroCore, Inc's (ECOR) CEO Dan Goldberger on Q2 2020 Results - Earnings Call Transcript
Shares of electroCore (NASDAQ:ECOR) fell 3.1% in after-market trading after the company reported Q2 results.
Received EUA and initiated gammaCore Sapphire CV distribution process for certain known or suspected COVID-19 patients experiencing asthma exacerbations
Conference Call to be Held at 4:30pm Eastern Time Conference Call to be Held at 4:30pm Eastern Time
Whether it’s all speculation or day trading, it seems there is no end to seeing major gains in small and micro-cap stocks that have positive announcements around anything to do with testing, v...
Initial distribution to hospitals and patients expected to begin on July 31st Initial distribution to hospitals and patients expected to begin on July 31st
Bioelectronic medicine's crucial role has come into focus with Covid-19, and a recent FDA approval practically assures ECOR stock's ascent. The post FDA Green Light Makes ElectroCore a Micro-...
Paper supports use of nVNS as a front-line therapy for acute and preventative treatment of cluster headache and as an effective option for the treatment of migraine headache Paper supports use...
BASKING RIDGE, N.J., July 16, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on July 14, 2020, the company’s cash was incorrectly stated as being as of the end of the f...
ElectroCore (ECOR) news for Monday concerning emergency authorization from the FDA for one of its drugs to treat coronavirus. The post ElectroCore News: Why ECOR Stock Is Skyrocketing 142% Tod...
Shares of electroCore Inc. ECOR, +142.94% more than doubled (up 155%) on very heavy volume in afternoon trading Monday, after the bioelectronic medicine company said it was issued an emergency...
Intended use allows gammaCore Sapphire CV use at home or in a healthcare setting Intended use allows gammaCore Sapphire CV use at home or in a healthcare setting
BASKING RIDGE, N.J., July 09, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Dan Goldberger, Chief Executi...
As the virus spreads, if you’re looking to bet against the market or hedge, our deep learning algorithms paired with out Artificial Intelligence (“AI”) data has some Top Shorts named for you t...
If you’re looking to hedge some downside, or if you think the market has gone too far to the upside, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identif...
Retail sales surging 18% in May fared well with the markets this morning, but with growing concerns over a Coronavirus resurgence, it's clear that volatility is just around the corner. We've u...
With the S&P 500, Nasdaq, and Dow going positive today, we link the markets are overextended. Our deep learning and AI has identified several Top Shorts today for you to hedge your portfolio w...
We have some buying this morning with markets recovering some of Thursday’s massive losses. However, it looks uneasy at best.
electroCore: Promising Product Means New Management Team Can Complete Unlikely Turnaround
electroCore, Inc. (ECOR) CEO Dan Goldberger on Q1 2020 Results - Earnings Call Transcript
electroCore, Inc. (ECOR) delivered earnings and revenue surprises of -4.00% and 0.55%, respectively, for the quarter ended March 2020.
Daily Insider Ratings Round Up 4/16/20
BASKING RIDGE, N.J., April 17, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced ...
ITP program reimbursing for gammaCore™ extended to Sept. 30, 2020 ITP program reimbursing for gammaCore™ extended to Sept. 30, 2020
ElectroCore, Inc (NASDAQ: ECOR) shares are trading higher on Friday, after the company announced it has submitted an emergency use authorization application to the FDA to allow the study and u...
Top Ranked Momentum Stocks to Buy for April 3rd
BASKING RIDGE, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has submitted an...
Top Ranked Momentum Stocks to Buy for March 31st
Approval makes novel non-invasive vagus nerve stimulation therapy available for prevention as well as acute treatment of migraines in adults Approval makes novel non-invasive vagus nerve stimu...
BASKING RIDGE, N.J., March 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into a common...
John Gandolfo, Tom Patton and Peter Cuneo to join the Board, adding significant medical technology operational, financial and turn-around experience John Gandolfo, Tom Patton and Peter Cuneo t...
About ECOR
electroCore, a commercial stage medical device company, engages in the development and commercialization of a range of patient administered non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is hea... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Jun 22, 2018 |
| CEO Daniel S. Goldberger | Employees 51 |
| Stock Exchange NASDAQ | Ticker Symbol ECOR |
Financial Performance
In 2019, electroCore's revenue was $2.39 million, an increase of 140.72% compared to the previous year's $992,953. Losses were -$45.15 million, -19.12% less than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for electroCore stock is "Buy." The 12-month stock price forecast is 3.50, which is an increase of 14.75% from the latest price.